Bicycle Therapeutics plc
Bicycle Therapeutics plc (BCYC) Revenue
Annual & quarterly revenue history · segment & region breakdown
BCYC · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsBicycle Therapeutics plc trailing twelve-month (TTM) revenue is $0.06B, an increase of 105.77% year-over-year from $0.07B in FY2025.
Revenue trend
2025 – 2016 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.07B | +$0.04B | +105.77% |
| 2024-12-31 | $0.04B | +$0.01B | +30.76% |
| 2023-12-31 | $0.03B | +$0.01B | +86.52% |
| 2022-12-31 | $0.01B | +$0.00B | +23.65% |
| 2021-12-31 | $0.01B | +$0.00B | +12.58% |
| 2020-12-31 | $0.01B | -$0.00B | -24.72% |
| 2019-12-31 | $0.01B | +$0.01B | +93.40% |
| 2018-12-31 | $0.01B | +$0.01B | +246.41% |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare BCYC revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Bicycle Therapeutics plc receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Bicycle Therapeutics plc reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Bicycle Therapeutics plc's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
BCYC revenue · 4 questionsBCYC's trailing twelve-month (TTM) revenue is $0.06B. That is an increase of 105.77% year-over-year from $0.07B in FY2025.
▸ Source: FMP · Bicycle Therapeutics plc SEC filings · GAAP · Bicycle Therapeutics plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026